Prestige Consumer Healthcare completes LaCorium Acquisition and Prices $400 Million Notes Offering

Prestige Consumer Healthcare PBH has completed its acquisition of LaCorium Health, a therapeutic skincare company, for approximately $150 million . LaCorium generates about $40 million in annual revenue and is expected to contribute roughly $12 million in EBITDA once integrated, adding to Prestige's branded over-the-counter portfolio.

Alongside the deal, Prestige priced a $400 million offering of 6.25% senior notes due 2034, with proceeds earmarked to redeem $400 million of existing 5.125% senior notes due January 2028. The refinancing trades a lower coupon maturing in two years for a higher one maturing in eight, extending Prestige's debt runway at the cost of a higher near-term interest expense.

The combination of a bolt-on acquisition and a balance-sheet refinancing reflects Prestige's steady-growth playbook in the OTC consumer-health space, where demand has remained resilient. LaCorium gives the company a stronger platform in dermatology-adjacent skincare as it continues to build out its branded product portfolio.